Jung Hee - THC Biomed CFO CoFounder
| THCBF Stock | USD 0 0.00 0.00% |
Insider
Jung Hee is CFO CoFounder of THC Biomed Intl
| Web | https://thcbiomed.com |
THC Biomed Management Efficiency
The company has return on total asset (ROA) of (0.1528) % which means that it has lost $0.1528 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4132) %, meaning that it generated substantial loss on money invested by shareholders. THC Biomed's management efficiency ratios could be used to measure how well THC Biomed manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Brian MD | Rezolute | 49 | |
| Edward Calamai | DiaMedica Therapeutics | N/A | |
| Dominic Cundari | DiaMedica Therapeutics | 73 | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Robyn Sweinhart | Rezolute | N/A | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| Daniel Ryweck | Silo Pharma | 59 | |
| , MBA | Molecular Partners AG | 51 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| LLM JD | Rezolute | 63 | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Antony CPA | Forte Biosciences | 57 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Steven Ruhl | Forte Biosciences | 67 | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.41 | |||
| Return On Asset | -0.15 |
THC Biomed Intl Leadership Team
Elected by the shareholders, the THC Biomed's board of directors comprises two types of representatives: THC Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of THC. The board's role is to monitor THC Biomed's management team and ensure that shareholders' interests are well served. THC Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, THC Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Damien Reynolds, Chief Officer | ||
| Dianne FCIS, Co Sec | ||
| John Miller, CEO Pres | ||
| Jung Hee, CFO CoFounder |
THC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is THC Biomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | |||
| Return On Asset | -0.15 | |||
| Profit Margin | (1.56) % | |||
| Operating Margin | (1.83) % | |||
| Current Valuation | 6.56 M | |||
| Shares Outstanding | 163.96 M | |||
| Shares Owned By Insiders | 29.02 % | |||
| Price To Book | 0.73 X | |||
| Price To Sales | 1.37 X | |||
| Revenue | 3.34 M |
Currently Active Assets on Macroaxis
Other Information on Investing in THC Pink Sheet
THC Biomed financial ratios help investors to determine whether THC Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in THC with respect to the benefits of owning THC Biomed security.